drugset / Trial / NCT06978829
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Phase 2
Recruiting
42 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NaSingle-groupOpen-labelTreatment
Summary
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2027-03-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |